Disc Medicine (IRON) Competitors $60.74 +1.36 (+2.29%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$60.75 +0.01 (+0.02%) As of 07/22/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRON vs. ROIV, LEGN, ELAN, RGC, RVMD, GRFS, TGTX, NUVL, RYTM, and CRSPShould you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Rhythm Pharmaceuticals (RYTM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Disc Medicine vs. Its Competitors Roivant Sciences Legend Biotech Elanco Animal Health Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Nuvalent Rhythm Pharmaceuticals CRISPR Therapeutics Roivant Sciences (NASDAQ:ROIV) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Which has more volatility and risk, ROIV or IRON? Roivant Sciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Does the media prefer ROIV or IRON? In the previous week, Disc Medicine had 11 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for Disc Medicine and 2 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.63 beat Disc Medicine's score of 0.45 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Disc Medicine 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of ROIV or IRON? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 4.2% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate ROIV or IRON? Roivant Sciences currently has a consensus price target of $16.50, suggesting a potential upside of 43.48%. Disc Medicine has a consensus price target of $95.73, suggesting a potential upside of 57.60%. Given Disc Medicine's higher probable upside, analysts clearly believe Disc Medicine is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has stronger valuation & earnings, ROIV or IRON? Disc Medicine has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$29.05M269.12-$171.98M-$0.25-46.00Disc MedicineN/AN/A-$109.36M-$3.92-15.49 Is ROIV or IRON more profitable? Disc Medicine has a net margin of 0.00% compared to Roivant Sciences' net margin of -225.71%. Roivant Sciences' return on equity of -14.76% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-225.71% -14.76% -13.69% Disc Medicine N/A -22.61%-21.07% SummaryRoivant Sciences beats Disc Medicine on 9 of the 16 factors compared between the two stocks. Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRON vs. The Competition Export to ExcelMetricDisc MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.06B$2.93B$5.49B$9.45BDividend YieldN/A2.49%4.01%4.03%P/E Ratio-15.4920.5328.4719.90Price / SalesN/A266.81410.1985.18Price / CashN/A41.6635.9658.29Price / Book4.097.808.365.67Net Income-$109.36M-$55.10M$3.24B$258.18M7 Day Performance5.93%4.62%3.13%2.81%1 Month Performance17.53%17.99%10.98%13.53%1 Year Performance31.70%2.21%34.54%17.68% Disc Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRONDisc Medicine3.3763 of 5 stars$60.74+2.3%$95.73+57.6%+32.2%$2.06BN/A-15.4930Analyst ForecastROIVRoivant Sciences2.8165 of 5 stars$11.48+0.3%$16.50+43.7%+3.3%$7.78B$29.05M-45.92860Positive NewsLEGNLegend Biotech3.7124 of 5 stars$42.23+1.5%$73.33+73.7%-25.3%$7.64B$627.24M-71.582,609Positive NewsAnalyst RevisionELANElanco Animal Health2.0725 of 5 stars$14.67-0.8%$16.00+9.1%+17.0%$7.34B$4.44B19.829,000Analyst RevisionRGCRegencell Bioscience0.2406 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010RVMDRevolution Medicines4.6121 of 5 stars$38.42+0.3%$68.91+79.4%-20.2%$7.13B$11.58M-9.61250GRFSGrifols3.3098 of 5 stars$10.00+0.6%$10.30+3.0%+22.6%$6.83B$7.81B8.5523,822Upcoming EarningsTGTXTG Therapeutics3.7308 of 5 stars$37.42-1.3%$43.80+17.0%+82.8%$6.02B$329M157.96290Positive NewsNUVLNuvalent3.3425 of 5 stars$82.46-1.1%$119.60+45.0%-0.6%$5.99BN/A-18.7840Analyst ForecastRYTMRhythm Pharmaceuticals3.2945 of 5 stars$88.63-0.6%$91.93+3.7%+76.4%$5.68B$130.13M-31.54140CRSPCRISPR Therapeutics1.96 of 5 stars$65.33+0.3%$71.75+9.8%+17.2%$5.62B$37.31M-14.45460Analyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Roivant Sciences Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Regencell Bioscience Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Rhythm Pharmaceuticals Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRON) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRON Stock Alerts